Science1 distinct publisher3 min readPublished
HKUST and CUHK researchers report in Nature Communications that thermodynamic timing lets amplification and CRISPR detection share a single sealed tube, reaching 1 aM in 30 minutes. The announcement leaves out the clinical denominator.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
Begin with the timing problem, because it is why one-pot nucleic acid tests have stayed in the lab. Inside a sealed tube, amplification is trying to build up a target while the CRISPR enzyme is already eating it, and the two reactions draw on the same reagents; trigger detection too early and the whole thing stalls [5]. Previous fixes tuned reagent concentrations, physically separated the steps, or asked a human to intervene at the right moment, which the HKUST group describes as fragile and hard to scale [6].
TEMPO puts the delay into the chemistry instead. One primer binds cleanly and does the initial copying. Its partner carries an intentional, energetically unfavourable mismatch and stays inert until enough target has accumulated to cross a thermodynamic threshold, at which point it engages and writes a PAM site into the product, switching the CRISPR enzyme on [7]. The consequence for coverage is real: because the enzyme's start signal is installed by the primer rather than borrowed from the target, sites with no natural PAM nearby become reachable, and single-letter discrimination survives [9].
The load-bearing result is the ordinary differential equation model that predicted the delayed, threshold-dependent switch-on [8]; it is what turns primer design from trial and error into something you can specify in advance, and it matters more than the tube itself. That is the claim other labs should try to break first: a platform that works only for the primer pairs its inventors already found is just a demonstration.
Now the sensitivity figure, which deserves unit conversion rather than applause. One attomolar [10] is 1e-18 mol/L; multiplied by 6.022e23 molecules per mole it works out to roughly 0.6 target copies per microlitre [12]. So the assay is operating in single-digit-copy territory, where the binding physics matters less than how much sample you put in the tube and whether the copies you need happen to be in it. At that concentration, Poisson sampling sets the floor, not the binding chemistry.
The announcement leaves out a denominator: there is no clinical specimen count, no head-to-head concordance against PCR, and no false-positive rate in the material available [11], even as the platform is framed as bridging the gap between existing rapid tests and laboratory nucleic acid diagnostics for surveillance and genetic screening [13]. Demonstrations are cited for influenza, COVID-19 and HIV [4], and the paper's own framing is point-of-care SNP genotyping [3].
My read: the thermodynamic timing rule is the transferable contribution and it is a good one. Treat 30 minutes and 1 aM [1][10] as a ceiling measured under laboratory control. Inhibitors in raw sample, reagent stability without a cold chain, and a user misreading a faint signal are the things that break decentralised testing, and none of them show up in this number.
Ranked by verification strength, evidence, and original report placement.
A team at The Hong Kong University of Science and Technology developed a one-pot testing platform called TEMPO that uses a single reaction tube and can give results described as comparable to professional laboratory tests in as little as 30 minutes.
TEMPO stands for Thermodynamically Encoded Molecular Programming for One-Pot Diagnostics and was jointly developed by a team led by Hsing I-Ming, a professor in HKUST's Department of Chemical and Biological Engineering, with researchers from The Chinese University of Hong Kong.
The study, titled 'Thermodynamically programmed one-pot CRISPR platform for point-of-care SNP genotyping', is published in Nature Communications.
The platform has demonstrated applications in detecting viral infections including influenza, COVID-19 and HIV, and the team says it opens possibilities for rapid screening of hereditary diseases.
In a one-pot CRISPR test, amplification and CRISPR detection compete for the same reagents in a sealed tube: amplification needs to build up the target while the CRISPR enzyme immediately starts consuming it, and starting the second step too early stalls the reaction.
Earlier attempts to control reaction order adjusted reagent concentrations, physically separated individual steps, or relied on manual intervention; these approaches often lacked robustness and were difficult to scale.
Distinct publishers with included, body-backed reporting in this cluster.
phys.org
1 article · August 31, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
science
HKUST's 4,116-city model finds more than a tenth of sustainability gains beyond city limits1 distinct publisher
science
Narwhal tusks hide two spirals twisting against each other, and the mismatch is the point3 distinct publishers
science
Mount Sinai puts a youth protein on aging microglia, and the mice answer1 distinct publisher
science
Half the resistance genes in livestock manure also show up in 875 wild farm mice1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Peer-reviewed mechanism, unquantified clinical claims
Two very different tiers sit in the same announcement. The chemistry — mismatched primer, thermodynamic threshold, primer-installed PAM, the ODE model — is specific, internally coherent and has passed Nature Communications review. The performance side thins out fast: 1 aM is a number, but 'fully concordant with qPCR' and 'real clinical specimens' are adjectives, and the only clinical count in the whole piece is 20 genomic samples.
Publication, no users
Everything reported happened inside the originating labs. A paper, a chip built by the same team, 20 genomic samples run by the same team — no second group, no clinic pilot, no regulator, no manufacturer. The account itself says the team is still working to expand the platform, which is where adoption stands.
Headline is a bathroom, evidence is a bench
'At-home testing' does the work of a product claim on the strength of a limit-of-detection figure and a set of validation runs whose denominators are missing. The gap is not in the chemistry, which is modest about itself; it is in the leap from 1 aM — about 0.6 copies in a microlitre — to a consumer kit, with no specificity figure and no regulatory step named in between.
University announcement, relayed intact
This is HKUST describing HKUST's result, with the corresponding author quoted three times and no other voice present; phys.org's role is transmission rather than scrutiny. That is the standard incentive shape for an institutional research announcement — emphasise the reconfigurable platform and the home-testing horizon, leave the specificity table in the paper.
Facts are firm, significance is not
We can be fairly sure what was claimed and published; we cannot be sure what it means clinically. A single relayed announcement, peer-reviewed underneath but unexamined by anyone else, supports confident reporting of the mechanism and much weaker conclusions about diagnostic performance.